Skip to main content
Top
Published in: Hereditary Cancer in Clinical Practice 1/2019

Open Access 01-12-2019 | Care | Research

Recommended care and care adherence following a diagnosis of Lynch syndrome: a mixed-methods study

Authors: Kathleen F. Mittendorf, Jessica Ezzell Hunter, Jennifer L. Schneider, Elizabeth Shuster, Alan F. Rope, Jamilyn Zepp, Marian J. Gilmore, Kristin R. Muessig, James V. Davis, Tia L. Kauffman, Kellene M. Bergen, Georgia L. Wiesner, Louise S. Acheson, Susan K. Peterson, Sapna Syngal, Jacob A. Reiss, Katrina A. B. Goddard

Published in: Hereditary Cancer in Clinical Practice | Issue 1/2019

Login to get access

Abstract

Background

Lynch syndrome (LS) is the most common hereditary colorectal cancer (CRC) syndrome. This study assesses trends in diagnosis of LS and adherence to recommended LS-related care in a large integrated healthcare organization (~ 575,000 members).

Methods

Electronic medical record (EMR) data (1999–2015) were examined to identify patients with a diagnosis of LS. We examined their LS-associated care recommendations and adherence to these recommendations. Qualitative patient and provider interviews were conducted with the aim of identifying opportunities for improved care delivery.

Results

We identified 74 patients with a diagnosis of LS; 64% were diagnosed with a LS-related malignancy prior to their diagnosis of LS. The time to LS diagnosis following development of a LS-related cancer decreased over time: before 2009 11% of individuals received a diagnosis of LS within 1 year of developing a LS-related cancer compared to 83% after 2009 (p < 0.0001). Colonoscopy recommendations were documented in the EMR for almost all patients with LS (96%). Documentation of other recommendations for cancer surveillance was less commonly found. Overall, patient adherence to colonoscopy was high (M = 81.5%; SD = 32.7%), and adherence to other recommendations varied. To improve care coordination, patients and providers suggested providing automated reminder prompts for LS-related surveillance, adding a LS-specific diagnosis code, and providing guidelines for LS-related surveillance in the EMR.

Conclusions

We identified fewer than expected patients with LS in our large care system, indicating that there is still a diagnostic care gap. However, patients with LS were likely to receive and follow CRC surveillance recommendations. Recommendations for and adherence to extracolonic surveillance were variable. Improved care coordination and clearer documentation of the LS diagnosis is needed.
Literature
1.
go back to reference Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26(35):5783–8.CrossRef Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26(35):5783–8.CrossRef
2.
go back to reference Vasen HF. Clinical description of the Lynch syndrome [hereditary nonpolyposis colorectal cancer (HNPCC)]. Familial Cancer. 2005;4(3):219–25.CrossRef Vasen HF. Clinical description of the Lynch syndrome [hereditary nonpolyposis colorectal cancer (HNPCC)]. Familial Cancer. 2005;4(3):219–25.CrossRef
3.
go back to reference Vasen HF, Mecklin JP, Khan PM, Lynch HT. The international collaborative group on hereditary non-polyposis colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34(5):424–5.CrossRef Vasen HF, Mecklin JP, Khan PM, Lynch HT. The international collaborative group on hereditary non-polyposis colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34(5):424–5.CrossRef
4.
go back to reference Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology. 1999;116(6):1453–6.CrossRef Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology. 1999;116(6):1453–6.CrossRef
5.
go back to reference Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, et al. A National Cancer Institute workshop on hereditary nonpolyposis colorectal Cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst. 1997;89(23):1758–62.CrossRef Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, et al. A National Cancer Institute workshop on hereditary nonpolyposis colorectal Cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst. 1997;89(23):1758–62.CrossRef
6.
go back to reference Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261–8.CrossRef Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261–8.CrossRef
7.
go back to reference Bansidhar BJ, Silinsky J. History and pathogenesis of lynch syndrome. Clin Colon Rectal Surg. 2012;25(2):63–6.CrossRef Bansidhar BJ, Silinsky J. History and pathogenesis of lynch syndrome. Clin Colon Rectal Surg. 2012;25(2):63–6.CrossRef
8.
go back to reference Evans DG, Ingham SL. Reduced life expectancy seen in hereditary diseases which predispose to early-onset tumors. Appl Clin Genet. 2013;6:53–61.CrossRef Evans DG, Ingham SL. Reduced life expectancy seen in hereditary diseases which predispose to early-onset tumors. Appl Clin Genet. 2013;6:53–61.CrossRef
9.
go back to reference Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118(5):829–34.CrossRef Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118(5):829–34.CrossRef
10.
go back to reference National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology V1.2018 Genetic/Familial High-Risk Assessment: Colorectal. 2019. 2018 February 25. Available from: http://www.nccn.org/. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology V1.2018 Genetic/Familial High-Risk Assessment: Colorectal. 2019. 2018 February 25. Available from: http://​www.​nccn.​org/​.
11.
go back to reference Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352(18):1851–60.CrossRef Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352(18):1851–60.CrossRef
12.
go back to reference Julie C, Tresallet C, Brouquet A, Vallot C, Zimmermann U, Mitry E, et al. Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening. Am J Gastroenterol. 2008;103(11):2825–35 quiz 36.CrossRef Julie C, Tresallet C, Brouquet A, Vallot C, Zimmermann U, Mitry E, et al. Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening. Am J Gastroenterol. 2008;103(11):2825–35 quiz 36.CrossRef
13.
go back to reference Cross DS, Rahm AK, Kauffman TL, Webster J, Le AQ, Spencer Feigelson H, et al. Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancer. Genet Med. 2013;15(12):933–40.CrossRef Cross DS, Rahm AK, Kauffman TL, Webster J, Le AQ, Spencer Feigelson H, et al. Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancer. Genet Med. 2013;15(12):933–40.CrossRef
14.
go back to reference Beamer LC, Grant ML, Espenschied CR, Blazer KR, Hampel HL, Weitzel JN, et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol. 2012;30(10):1058–63.CrossRef Beamer LC, Grant ML, Espenschied CR, Blazer KR, Hampel HL, Weitzel JN, et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol. 2012;30(10):1058–63.CrossRef
15.
go back to reference Mange S, Bellcross C, Cragun D, Duquette D, Gorman L, Hampel H, et al. Creation of a network to promote universal screening for Lynch syndrome: the LynchSyndrome screening network. J Genet Couns. 2015;24(3):421–7.CrossRef Mange S, Bellcross C, Cragun D, Duquette D, Gorman L, Hampel H, et al. Creation of a network to promote universal screening for Lynch syndrome: the LynchSyndrome screening network. J Genet Couns. 2015;24(3):421–7.CrossRef
16.
go back to reference Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K, Peltomaki P, Aaltonen LA, Mecklin JP. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol. 2009;27(28):4793–7.CrossRef Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K, Peltomaki P, Aaltonen LA, Mecklin JP. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol. 2009;27(28):4793–7.CrossRef
17.
go back to reference Newton K, Green K, Lalloo F, Evans DG, Hill J. Colonoscopy screening compliance and outcomes in patients with Lynch syndrome. Color Dis. 2015;17(1):38–46.CrossRef Newton K, Green K, Lalloo F, Evans DG, Hill J. Colonoscopy screening compliance and outcomes in patients with Lynch syndrome. Color Dis. 2015;17(1):38–46.CrossRef
18.
go back to reference Pylvanainen K, Kairaluoma M, Mecklin JP. Compliance and satisfaction with long-term surveillance in Finnish HNPCC families. Familial Cancer. 2006;5(2):175–8.CrossRef Pylvanainen K, Kairaluoma M, Mecklin JP. Compliance and satisfaction with long-term surveillance in Finnish HNPCC families. Familial Cancer. 2006;5(2):175–8.CrossRef
19.
go back to reference Hadley DW, Jenkins JF, Dimond E, de Carvalho M, Kirsch I, Palmer CG. Colon cancer screening practices after genetic counseling and testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2004;22(1):39–44.CrossRef Hadley DW, Jenkins JF, Dimond E, de Carvalho M, Kirsch I, Palmer CG. Colon cancer screening practices after genetic counseling and testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2004;22(1):39–44.CrossRef
20.
go back to reference Stoffel EM, Mercado RC, Kohlmann W, Ford B, Grover S, Conrad P, et al. Prevalence and predictors of appropriate colorectal cancer surveillance in Lynch syndrome. Am J Gastroenterol. 2010;105(8):1851–60.CrossRef Stoffel EM, Mercado RC, Kohlmann W, Ford B, Grover S, Conrad P, et al. Prevalence and predictors of appropriate colorectal cancer surveillance in Lynch syndrome. Am J Gastroenterol. 2010;105(8):1851–60.CrossRef
21.
go back to reference Burton-Chase AM, Hovick SR, Sun CC, Boyd-Rogers S, Lynch PM, Lu KH, et al. Gynecologic cancer screening and communication with health care providers in women with Lynch syndrome. Clin Genet. 2014;86(2):185–9.CrossRef Burton-Chase AM, Hovick SR, Sun CC, Boyd-Rogers S, Lynch PM, Lu KH, et al. Gynecologic cancer screening and communication with health care providers in women with Lynch syndrome. Clin Genet. 2014;86(2):185–9.CrossRef
22.
go back to reference Yurgelun MB, Mercado R, Rosenblatt M, Dandapani M, Kohlmann W, Conrad P, et al. Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome. Gynecol Oncol. 2012;127(3):544–51.CrossRef Yurgelun MB, Mercado R, Rosenblatt M, Dandapani M, Kohlmann W, Conrad P, et al. Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome. Gynecol Oncol. 2012;127(3):544–51.CrossRef
23.
go back to reference Clarke EV, Muessig KR, Zepp J, Hunter JE, Syngal S, Acheson LS, et al. Implementation of a Systematic Tumor Screening Program for Lynch Syndrome in an Integrated Health Care Setting. Fam Cancer. 2019;18:317–25.CrossRef Clarke EV, Muessig KR, Zepp J, Hunter JE, Syngal S, Acheson LS, et al. Implementation of a Systematic Tumor Screening Program for Lynch Syndrome in an Integrated Health Care Setting. Fam Cancer. 2019;18:317–25.CrossRef
24.
go back to reference Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.CrossRef Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.CrossRef
25.
go back to reference Schneider JL, Goddard KAB, Muessig KR, Davis JV, Rope AF, Hunter JE, et al. Patient and provider perspectives on adherence to and care coordination of lynch syndrome surveillance recommendations: findings from qualitative interviews. Hered Cancer Clin Pract. 2018;16:11.CrossRef Schneider JL, Goddard KAB, Muessig KR, Davis JV, Rope AF, Hunter JE, et al. Patient and provider perspectives on adherence to and care coordination of lynch syndrome surveillance recommendations: findings from qualitative interviews. Hered Cancer Clin Pract. 2018;16:11.CrossRef
26.
go back to reference Busing FM, Weaver B, Dubois S. 2 x 2 tables: a note on Campbell's recommendation. Stat Med. 2016;35(8):1354–8.CrossRef Busing FM, Weaver B, Dubois S. 2 x 2 tables: a note on Campbell's recommendation. Stat Med. 2016;35(8):1354–8.CrossRef
27.
go back to reference Campbell I. Chi-squared and Fisher-Irwin tests of two-by-two tables with small sample recommendations. Stat Med. 2007;26(19):3661–75.CrossRef Campbell I. Chi-squared and Fisher-Irwin tests of two-by-two tables with small sample recommendations. Stat Med. 2007;26(19):3661–75.CrossRef
28.
go back to reference Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med. 2009;11(1):42–65.CrossRef Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med. 2009;11(1):42–65.CrossRef
29.
go back to reference Evaluation of Genomic Applications in P, Prevention Working G. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009;11(1):35–41.CrossRef Evaluation of Genomic Applications in P, Prevention Working G. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009;11(1):35–41.CrossRef
30.
go back to reference Corbin J, Strauss A. Basics of Qualitative Research: Techniques and Procedures for Developing Grounded Theory, vol. 2008. 4th ed. Thousand Oaks: SAGE Publishing; 2008.CrossRef Corbin J, Strauss A. Basics of Qualitative Research: Techniques and Procedures for Developing Grounded Theory, vol. 2008. 4th ed. Thousand Oaks: SAGE Publishing; 2008.CrossRef
31.
go back to reference Patton MQ. Qualitative research and evaluation methods. 3rd ed. Thousand Oaks: Sage Publications; 2002. Patton MQ. Qualitative research and evaluation methods. 3rd ed. Thousand Oaks: Sage Publications; 2002.
32.
go back to reference Strauss A, Corbin J. Basics of qualitative research: techniques and procedures for developing grounded theory. Thousand Oaks: Sage Publications; 2008. Strauss A, Corbin J. Basics of qualitative research: techniques and procedures for developing grounded theory. Thousand Oaks: Sage Publications; 2008.
33.
go back to reference Bernard H, Ryan G. Analyzing qualitative data: systematic approaches. Los Angeles: Sage Publications; 2010. Bernard H, Ryan G. Analyzing qualitative data: systematic approaches. Los Angeles: Sage Publications; 2010.
35.
go back to reference National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology V1.2014 Genetic/Familial High-Risk Assessment: Colorectal. 2014 03.19.2014. Available from: http://www.nccn.org/. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology V1.2014 Genetic/Familial High-Risk Assessment: Colorectal. 2014 03.19.2014. Available from: http://​www.​nccn.​org/​.
Metadata
Title
Recommended care and care adherence following a diagnosis of Lynch syndrome: a mixed-methods study
Authors
Kathleen F. Mittendorf
Jessica Ezzell Hunter
Jennifer L. Schneider
Elizabeth Shuster
Alan F. Rope
Jamilyn Zepp
Marian J. Gilmore
Kristin R. Muessig
James V. Davis
Tia L. Kauffman
Kellene M. Bergen
Georgia L. Wiesner
Louise S. Acheson
Susan K. Peterson
Sapna Syngal
Jacob A. Reiss
Katrina A. B. Goddard
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Hereditary Cancer in Clinical Practice / Issue 1/2019
Electronic ISSN: 1897-4287
DOI
https://doi.org/10.1186/s13053-019-0130-8

Other articles of this Issue 1/2019

Hereditary Cancer in Clinical Practice 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine